Review





Similar Products

96
Miltenyi Biotec cd45 immune cells
Cd45 Immune Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd45/CD45+MicroBeads%2C+human/pm42982986-42-4-13
Average 96 stars, based on 1 article reviews
cd45 immune cells - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Sino Biological cd45
Cd45, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd45/Human+CD45-AB+Protein/pm42896768-48-33-34
Average 94 stars, based on 1 article reviews
cd45 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Miltenyi Biotec cd45 viogreen
Cd45 Viogreen, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd45/CD45+Antibody%2C+anti-human%2C+REAfinity/pm42985785-64-23-38
Average 96 stars, based on 1 article reviews
cd45 viogreen - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Illumina Inc genomics 1000212 cosmx human rna 1000 plex assay nanostring cmx h uscp 1kp r infiniumcoreexome 24v1 4 a1 illumina 20024662 human io panck cd45
Genomics 1000212 Cosmx Human Rna 1000 Plex Assay Nanostring Cmx H Uscp 1kp R Infiniumcoreexome 24v1 4 A1 Illumina 20024662 Human Io Panck Cd45, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd45/Infinium+CoreExome-24+v1%2E3+Kit/pm42986753-290-163-173
Average 94 stars, based on 1 article reviews
genomics 1000212 cosmx human rna 1000 plex assay nanostring cmx h uscp 1kp r infiniumcoreexome 24v1 4 a1 illumina 20024662 human io panck cd45 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Elabscience Biotechnology cd45
Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, CD4 + helper T cells, and <t>CD45</t> + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Cd45, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd45/PerCP+Anti-Human+CD45+Antibody/pmc13774206-48-21-23
Average 94 stars, based on 1 article reviews
cd45 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Miltenyi Biotec antibodies against human cd45
a. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of <t>human</t> <t>CD45-positive</t> (hCD45⁺) cells in peripheral blood during treatment with ASNase (25 IU/mouse every 8 days) for 5 weeks. Treatment was discontinued following sacrifice of the vehicle-treated mice, and the remaining mice were monitored until reaching the experimental endpoint. Each dot represents an individual mouse. b. Bodyweight of mice shown in , expressed as the percentage of baseline bodyweight. Dots represent group means; error bars indicate SEM.
Antibodies Against Human Cd45, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd45/CD45+Antibody%2C+anti-human%2C+REAfinity/bio_rxiv__64898__2026__11__02__763650-299-18-22
Average 96 stars, based on 1 article reviews
antibodies against human cd45 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Bio-Rad mouse antihuman cd45 alexa fluor 647
a. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of <t>human</t> <t>CD45-positive</t> (hCD45⁺) cells in peripheral blood during treatment with ASNase (25 IU/mouse every 8 days) for 5 weeks. Treatment was discontinued following sacrifice of the vehicle-treated mice, and the remaining mice were monitored until reaching the experimental endpoint. Each dot represents an individual mouse. b. Bodyweight of mice shown in , expressed as the percentage of baseline bodyweight. Dots represent group means; error bars indicate SEM.
Mouse Antihuman Cd45 Alexa Fluor 647, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd45/Mouse+anti+Human+CD45/pmc13691775-62-47-55
Average 93 stars, based on 1 article reviews
mouse antihuman cd45 alexa fluor 647 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

95
Miltenyi Biotec cd45 microbeads
Tumor-infiltrating immune cells were isolated from vitally stored tumor tissue using <t>CD45</t> MicroBeads as described in “Materials and Methods”. Spectral flow cytometry was done following staining against a panel of surface antigens to discriminate immune cell subtypes. A Gating strategy. B Quantification and stratification by patient’s outcome (dead/alive by data cutoff: July 31st 2025). Specific immune cell subtypes were identified by their expression profile. Given is the % of positive cells after gating of the viable immune cells with additional hierarchical sub-gating to distinguish lymphoid and myeloid compartments. For M1/M2-like macrophages, the ratio was calculated by dividing the value of CD3 - CD14 + macrophages by the value of CD3 - CD163 + M2-like macrophages. N = 25, Unpaired two-tailed Student’s t test or Mann–Whitney U test, * p < 0.05.
Cd45 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd45/CD45+(TIL)+MicroBeads%2C+human/pmc13680621-103-11-13
Average 95 stars, based on 1 article reviews
cd45 microbeads - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Agilent technologies percp conjugated anti human cd45 antibody
Tumor-infiltrating immune cells were isolated from vitally stored tumor tissue using <t>CD45</t> MicroBeads as described in “Materials and Methods”. Spectral flow cytometry was done following staining against a panel of surface antigens to discriminate immune cell subtypes. A Gating strategy. B Quantification and stratification by patient’s outcome (dead/alive by data cutoff: July 31st 2025). Specific immune cell subtypes were identified by their expression profile. Given is the % of positive cells after gating of the viable immune cells with additional hierarchical sub-gating to distinguish lymphoid and myeloid compartments. For M1/M2-like macrophages, the ratio was calculated by dividing the value of CD3 - CD14 + macrophages by the value of CD3 - CD163 + M2-like macrophages. N = 25, Unpaired two-tailed Student’s t test or Mann–Whitney U test, * p < 0.05.
Percp Conjugated Anti Human Cd45 Antibody, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd45/PerCP/pmc13679345-115-18-22
Average 95 stars, based on 1 article reviews
percp conjugated anti human cd45 antibody - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Bio-Rad anti cd45 alexa fluor 647
Tumor-infiltrating immune cells were isolated from vitally stored tumor tissue using <t>CD45</t> MicroBeads as described in “Materials and Methods”. Spectral flow cytometry was done following staining against a panel of surface antigens to discriminate immune cell subtypes. A Gating strategy. B Quantification and stratification by patient’s outcome (dead/alive by data cutoff: July 31st 2025). Specific immune cell subtypes were identified by their expression profile. Given is the % of positive cells after gating of the viable immune cells with additional hierarchical sub-gating to distinguish lymphoid and myeloid compartments. For M1/M2-like macrophages, the ratio was calculated by dividing the value of CD3 - CD14 + macrophages by the value of CD3 - CD163 + M2-like macrophages. N = 25, Unpaired two-tailed Student’s t test or Mann–Whitney U test, * p < 0.05.
Anti Cd45 Alexa Fluor 647, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+cd45/Mouse+anti+Human+CD45/pm42882818-64-43-48
Average 93 stars, based on 1 article reviews
anti cd45 alexa fluor 647 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, CD4 + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.

Journal: Frontiers in Pharmacology

Article Title: Anlotinib suppresses homologous recombination via the E2F8-RAD51 axis to activate STING immunity and potentiate PARP inhibitor synthetic lethality in resistant small cell lung cancer

doi: 10.3389/fphar.2026.1939827

Figure Lengend Snippet: Combination therapy activates innate immunity via the STING-TBK1-IRF3-IFNβ pathway and enhances T-cell function. (A) Western blot analysis of STING pathway components (TBK1, p-TBK1, p-IRF3, IFNβ, NF-κB) in H82R and H526R cells. (B) Schematic illustration of the multicellular tumor spheroid (MCT) model composed of H82R SCLC cells, MRC-5 fibroblasts, HUVECs, and PBMCs. (C) Representative bright-field images of MCTs after treatment. Scale bar, 100 μm. (D) Flow cytometry analysis of CD8 + cytotoxic T cells, CD4 + helper T cells, and CD45 + HLA-DR + activated immune cells in MCTs (left) and quantification of cell percentages (right). All experiments were performed independently three times. n = 3 biologically independent replicates. The Student’s t-test was used to estimate the significance of the difference between two groups. Comparisons among multiple groups were performed by one-way ANOVA followed by Tukey’s post hoc test. Data were presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.

Article Snippet: After treatment, MCTs were dissociated into single cells and stained with fluorescently labeled antibodies against CD8 (E-AB-F1109C, Elabscience), CD4 (E-AB-F1110E, Elabscience), CD45 (E-AB-F1137F, Elabscience) and HLA-DR (E-AB-F1111D, Elabscience).

Techniques: Cell Function Assay, Western Blot, Analysis, Flow Cytometry

a. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood during treatment with ASNase (25 IU/mouse every 8 days) for 5 weeks. Treatment was discontinued following sacrifice of the vehicle-treated mice, and the remaining mice were monitored until reaching the experimental endpoint. Each dot represents an individual mouse. b. Bodyweight of mice shown in , expressed as the percentage of baseline bodyweight. Dots represent group means; error bars indicate SEM.

Journal: bioRxiv

Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES

doi: 10.64898/2026.11.02.763650

Figure Lengend Snippet: a. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood during treatment with ASNase (25 IU/mouse every 8 days) for 5 weeks. Treatment was discontinued following sacrifice of the vehicle-treated mice, and the remaining mice were monitored until reaching the experimental endpoint. Each dot represents an individual mouse. b. Bodyweight of mice shown in , expressed as the percentage of baseline bodyweight. Dots represent group means; error bars indicate SEM.

Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using antibodies against human CD45 (Miltenyi Biotech, #130-110-632) or human CD19 (#12-0199-42).

Techniques:

a. Relative viability of leukemic cells isolated from mice treated with a single intravenous dose of ASNase (100 IU/mouse) or vehicle (n = 3 mice per group). Cells were treated ex vivo with a two-fold serial dilution of ASNase (maximum concentration 2000 mIU/mL) for 72 h before viability was assessed using CellTiter-Glo. Concentrations were log-transformed. Each dot represents the mean of three biological replicates; error bars indicate SD. b. Relative ASNS mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. **p = 0.0038 (unpaired two-tailed t-test). c. Relative ATF4 mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. *p = 0.0238 (unpaired two-tailed t-test). d. Automated capillary western blot (WES) showing ASNS protein expression in leukemic cells isolated from mice in a treated with ASNase or vehicle. β-Actin serves as the loading control. Each lane is a biological replicate. e. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood. Mice received vehicle, ASNase (25 IU/mouse, single dose; n = 3), GCN2-IN-6 (3 mg/kg, oral dose every 3.5 days; n = 3), or the combination (n = 3). No significant differences were observed between treatment groups before treatment (day 0). At day 7, all treatment groups showed reduced leukemic burden compared with vehicle (*p = 0.0300 for ASNase, **p = 0.0017 for GCN2-IN-6, ***p = 0.0009 for the combination; one-way ANOVA with Dunnett’s multiple-comparison correction). Dots represent group means; error bars indicate SEM.

Journal: bioRxiv

Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES

doi: 10.64898/2026.11.02.763650

Figure Lengend Snippet: a. Relative viability of leukemic cells isolated from mice treated with a single intravenous dose of ASNase (100 IU/mouse) or vehicle (n = 3 mice per group). Cells were treated ex vivo with a two-fold serial dilution of ASNase (maximum concentration 2000 mIU/mL) for 72 h before viability was assessed using CellTiter-Glo. Concentrations were log-transformed. Each dot represents the mean of three biological replicates; error bars indicate SD. b. Relative ASNS mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. **p = 0.0038 (unpaired two-tailed t-test). c. Relative ATF4 mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. *p = 0.0238 (unpaired two-tailed t-test). d. Automated capillary western blot (WES) showing ASNS protein expression in leukemic cells isolated from mice in a treated with ASNase or vehicle. β-Actin serves as the loading control. Each lane is a biological replicate. e. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood. Mice received vehicle, ASNase (25 IU/mouse, single dose; n = 3), GCN2-IN-6 (3 mg/kg, oral dose every 3.5 days; n = 3), or the combination (n = 3). No significant differences were observed between treatment groups before treatment (day 0). At day 7, all treatment groups showed reduced leukemic burden compared with vehicle (*p = 0.0300 for ASNase, **p = 0.0017 for GCN2-IN-6, ***p = 0.0009 for the combination; one-way ANOVA with Dunnett’s multiple-comparison correction). Dots represent group means; error bars indicate SEM.

Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using antibodies against human CD45 (Miltenyi Biotech, #130-110-632) or human CD19 (#12-0199-42).

Techniques: Isolation, Ex Vivo, Serial Dilution, Concentration Assay, Transformation Assay, Expressing, Two Tailed Test, Automated, Western Blot, Control, Comparison

a-d. Leukemic burden, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood, in T-ALL PDX models 1–4 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. e-f. Leukemic burden, measured as the percentage of human CD19-positive (hCD19⁺) cells in peripheral blood, in B-ALL PDX models 1 and 2 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. g. Spleen weight of AML PDX-bearing mice treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Spleens were collected at the experimental endpoint. Statistical significance was determined using the Kruskal-Wallis test. **p = 0.0012. h. Leukemic burden, measured as the percentage of hCD45⁺ cells in peripheral blood, in the AML PDX model following treatment with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML) with time and treatment as fixed effects. *p = 0.0325. i. Relative tumor growth of an ovarian cancer cell line-derived xenograft (CDX) treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0008 j. Tumor volume of a neuroblastoma PDX treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 4 per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0002. k – n. Relative tumor growth of four TNBC PDX models treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 5 mice per group). Dots represent group means; error bars indicate SEM. Statistical analysis was performed using a linear mixed-effects model (REML). Significance is indicated in the figure.

Journal: bioRxiv

Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES

doi: 10.64898/2026.11.02.763650

Figure Lengend Snippet: a-d. Leukemic burden, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood, in T-ALL PDX models 1–4 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. e-f. Leukemic burden, measured as the percentage of human CD19-positive (hCD19⁺) cells in peripheral blood, in B-ALL PDX models 1 and 2 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. g. Spleen weight of AML PDX-bearing mice treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Spleens were collected at the experimental endpoint. Statistical significance was determined using the Kruskal-Wallis test. **p = 0.0012. h. Leukemic burden, measured as the percentage of hCD45⁺ cells in peripheral blood, in the AML PDX model following treatment with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML) with time and treatment as fixed effects. *p = 0.0325. i. Relative tumor growth of an ovarian cancer cell line-derived xenograft (CDX) treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0008 j. Tumor volume of a neuroblastoma PDX treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 4 per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0002. k – n. Relative tumor growth of four TNBC PDX models treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 5 mice per group). Dots represent group means; error bars indicate SEM. Statistical analysis was performed using a linear mixed-effects model (REML). Significance is indicated in the figure.

Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using antibodies against human CD45 (Miltenyi Biotech, #130-110-632) or human CD19 (#12-0199-42).

Techniques: Analysis, Derivative Assay, Xenograft Assay

Tumor-infiltrating immune cells were isolated from vitally stored tumor tissue using CD45 MicroBeads as described in “Materials and Methods”. Spectral flow cytometry was done following staining against a panel of surface antigens to discriminate immune cell subtypes. A Gating strategy. B Quantification and stratification by patient’s outcome (dead/alive by data cutoff: July 31st 2025). Specific immune cell subtypes were identified by their expression profile. Given is the % of positive cells after gating of the viable immune cells with additional hierarchical sub-gating to distinguish lymphoid and myeloid compartments. For M1/M2-like macrophages, the ratio was calculated by dividing the value of CD3 - CD14 + macrophages by the value of CD3 - CD163 + M2-like macrophages. N = 25, Unpaired two-tailed Student’s t test or Mann–Whitney U test, * p < 0.05.

Journal: Communications Medicine

Article Title: Perivascular spaces are associated with T cell trafficking and may have prognostic relevance in brain metastases

doi: 10.1038/s43856-026-01918-7

Figure Lengend Snippet: Tumor-infiltrating immune cells were isolated from vitally stored tumor tissue using CD45 MicroBeads as described in “Materials and Methods”. Spectral flow cytometry was done following staining against a panel of surface antigens to discriminate immune cell subtypes. A Gating strategy. B Quantification and stratification by patient’s outcome (dead/alive by data cutoff: July 31st 2025). Specific immune cell subtypes were identified by their expression profile. Given is the % of positive cells after gating of the viable immune cells with additional hierarchical sub-gating to distinguish lymphoid and myeloid compartments. For M1/M2-like macrophages, the ratio was calculated by dividing the value of CD3 - CD14 + macrophages by the value of CD3 - CD163 + M2-like macrophages. N = 25, Unpaired two-tailed Student’s t test or Mann–Whitney U test, * p < 0.05.

Article Snippet: Tumor-infiltrating immune cells were isolated from vitally stored tumor tissue using CD45 MicroBeads (Miltenyi Biotec, Cat: 130-118-780) according to the manufacturer’s protocol.

Techniques: Isolation, Tissue, Flow Cytometry, Staining, Immune Cell, Expressing, Two Tailed Test, MANN-WHITNEY

CD45 + and CD45 - cell fractions were examined for subtype-specific cell infiltration. Infiltration patterns were stratified by MRI-T2 weighted PVS grade in two distinct anatomic locations, i.e. ( A , C ) BG and ( B , D ) CSO. For CD45+ fractions, cytotoxicity and exhaustion-related markers were considered (CD3, CD8, PD1, CD183/CXCR3, Granzyme B, and IFNγ). In the CD45- fractions, markers associated with vascular and endothelial cells, involved in T cell trafficking (CD31/PECAM-1, CD54/ICAM-1, CXCL9/CXCL10, CD106/VCAM-1, and CD309/VEGFR2) were analyzed. Cell quantification was done by including the number of viable immune cells, positive for either marker. Given is the % of positive cells after gating of the viable immune cells with additional hierarchical sub-gating to distinguish cellular compartments and activation states. N = 16, Unpaired two-tailed Student’s t test or Mann–Whitney U test, * p < 0.05.

Journal: Communications Medicine

Article Title: Perivascular spaces are associated with T cell trafficking and may have prognostic relevance in brain metastases

doi: 10.1038/s43856-026-01918-7

Figure Lengend Snippet: CD45 + and CD45 - cell fractions were examined for subtype-specific cell infiltration. Infiltration patterns were stratified by MRI-T2 weighted PVS grade in two distinct anatomic locations, i.e. ( A , C ) BG and ( B , D ) CSO. For CD45+ fractions, cytotoxicity and exhaustion-related markers were considered (CD3, CD8, PD1, CD183/CXCR3, Granzyme B, and IFNγ). In the CD45- fractions, markers associated with vascular and endothelial cells, involved in T cell trafficking (CD31/PECAM-1, CD54/ICAM-1, CXCL9/CXCL10, CD106/VCAM-1, and CD309/VEGFR2) were analyzed. Cell quantification was done by including the number of viable immune cells, positive for either marker. Given is the % of positive cells after gating of the viable immune cells with additional hierarchical sub-gating to distinguish cellular compartments and activation states. N = 16, Unpaired two-tailed Student’s t test or Mann–Whitney U test, * p < 0.05.

Article Snippet: Tumor-infiltrating immune cells were isolated from vitally stored tumor tissue using CD45 MicroBeads (Miltenyi Biotec, Cat: 130-118-780) according to the manufacturer’s protocol.

Techniques: Marker, Activation Assay, Two Tailed Test, MANN-WHITNEY